146 related articles for article (PubMed ID: 35026408)
1. Early Antipsychotic Nonresponse as a Predictor of Nonresponse and Nonremission in Adolescents With Psychosis Treated With Aripiprazole or Quetiapine: Results From the TEA Trial.
Pagsberg AK; Krogmann A; Jeppesen P; von Hardenberg L; Klauber DG; Jensen KG; Rudå D; Decara MS; Jepsen JRM; Fagerlund B; Fink-Jensen A; Correll CU; Galling B
J Am Acad Child Adolesc Psychiatry; 2022 Aug; 61(8):997-1009. PubMed ID: 35026408
[TBL] [Abstract][Full Text] [Related]
2. Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial.
Pagsberg AK; Jeppesen P; Klauber DG; Jensen KG; Rudå D; Stentebjerg-Olesen M; Jantzen P; Rasmussen S; Saldeen EA; Lauritsen MG; Bilenberg N; Stenstrøm AD; Nyvang L; Madsen S; Werge TM; Lange T; Gluud C; Skoog M; Winkel P; Jepsen JRM; Fagerlund B; Correll CU; Fink-Jensen A
Lancet Psychiatry; 2017 Aug; 4(8):605-618. PubMed ID: 28599949
[TBL] [Abstract][Full Text] [Related]
3. Cardiometabolic Adverse Effects and Its Predictors in Children and Adolescents With First-Episode Psychosis During Treatment With Quetiapine-Extended Release Versus Aripiprazole: 12-Week Results From the Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis (TEA) Trial.
Jensen KG; Correll CU; Rudå D; Klauber DG; Decara MS; Fagerlund B; Jepsen JRM; Eriksson F; Fink-Jensen A; Pagsberg AK
J Am Acad Child Adolesc Psychiatry; 2019 Nov; 58(11):1062-1078. PubMed ID: 30858012
[TBL] [Abstract][Full Text] [Related]
4. Early antipsychotic response to aripiprazole in adolescents with schizophrenia: predictive value for clinical outcomes.
Correll CU; Zhao J; Carson W; Marcus R; McQuade R; Forbes RA; Mankoski R
J Am Acad Child Adolesc Psychiatry; 2013 Jul; 52(7):689-698.e3. PubMed ID: 23800482
[TBL] [Abstract][Full Text] [Related]
5. Quetiapine versus aripiprazole in children and adolescents with psychosis--protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial.
Pagsberg AK; Jeppesen P; Klauber DG; Jensen KG; Rudå D; Stentebjerg-Olesen M; Jantzen P; Rasmussen S; Saldeen EA; Lauritsen MB; Bilenberg N; Stenstrøm AD; Pedersen J; Nyvang L; Madsen S; Lauritsen MB; Vernal DL; Thomsen PH; Paludan J; Werge TM; Winge K; Juul K; Gluud C; Skoog M; Wetterslev J; Jepsen JR; Correll CU; Fink-Jensen A; Fagerlund B
BMC Psychiatry; 2014 Jul; 14():199. PubMed ID: 25015535
[TBL] [Abstract][Full Text] [Related]
6. Change and dispersion of QT interval during treatment with quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: results from the TEA trial.
Jensen KG; Gärtner S; Correll CU; Rudå D; Klauber DG; Stentebjerg-Olesen M; Fagerlund B; Jepsen JR; Fink-Jensen A; Juul K; Pagsberg AK
Psychopharmacology (Berl); 2018 Mar; 235(3):681-693. PubMed ID: 29185022
[TBL] [Abstract][Full Text] [Related]
7. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.
Kane JM; Correll CU; Goff DC; Kirkpatrick B; Marder SR; Vester-Blokland E; Sun W; Carson WH; Pikalov A; Assunção-Talbott S
J Clin Psychiatry; 2009 Oct; 70(10):1348-57. PubMed ID: 19906340
[TBL] [Abstract][Full Text] [Related]
8. Early nonresponse determined by the clinical global impressions scale predicts poorer outcomes in youth with schizophrenia spectrum disorders naturalistically treated with second-generation antipsychotics.
Stentebjerg-Olesen M; Jeppesen P; Pagsberg AK; Fink-Jensen A; Kapoor S; Chekuri R; Carbon M; Al-Jadiri A; Kishimoto T; Kane JM; Correll CU
J Child Adolesc Psychopharmacol; 2013 Dec; 23(10):665-75. PubMed ID: 24266529
[TBL] [Abstract][Full Text] [Related]
9. CYP2D6 Genotyping and Antipsychotic-Associated Extrapyramidal Adverse Effects in a Randomized Trial of Aripiprazole Versus Quetiapine Extended Release in Children and Adolescents, Aged 12-17 Years, With First Episode Psychosis.
Rudå D; Jensen KG; Decara MS; Klauber DG; Fagerlund B; Møllegaard JR; Linnet K; Werge T; Correll CU; Fink-Jensen A; Jürgens G; Pagsberg AK
J Clin Psychopharmacol; 2021 Nov-Dec 01; 41(6):667-672. PubMed ID: 34735099
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of early improvement in bipolar depression trials: a post-hoc pooled analysis of two 8-week aripiprazole studies.
Kemp DE; Calabrese JR; Eudicone JM; Ganocy S; Tran QV; McQuade RD; Marcus RN; Vester-Blokland E; Owen R; Carlson BX
Psychopharmacol Bull; 2010; 43(2):5-27. PubMed ID: 21052040
[TBL] [Abstract][Full Text] [Related]
11. Baseline Characteristics and Early Response at Week 1 Predict Treatment Outcome in Adolescents With Bipolar Manic or Mixed Episode Treated With Olanzapine: Results From a 3-Week, Randomized, Placebo-Controlled Trial.
Xiao L; Ganocy SJ; Findling RL; Chang K; DelBello MP; Kane JM; Tohen M; Xiang YT; Correll CU
J Clin Psychiatry; 2017; 78(9):e1158-e1166. PubMed ID: 28922591
[TBL] [Abstract][Full Text] [Related]
12. Early Nonresponse in the Antipsychotic Treatment of Acute Mania: A Criterion for Reconsidering Treatment? Results From an Individual Patient Data Meta-Analysis.
Welten CC; Koeter MW; Wohlfarth TD; Storosum JG; van den Brink W; Gispen-de Wied CC; Leufkens HG; Denys DA
J Clin Psychiatry; 2016 Sep; 77(9):e1117-e1123. PubMed ID: 27780320
[TBL] [Abstract][Full Text] [Related]
13. Early Efficacy of Antipsychotic Medications at Week 2 Predicts Subsequent Responses at Week 6 in a Large-scale Randomized Controlled Trial.
Tang Y; Wu Y; Li X; Hao Q; Deng W; Yue W; Yan H; Zhang Y; Tan L; Chen Q; Yang G; Lu T; Wang L; Yang F; Zhang F; Yang J; Li K; Lv L; Tan Q; Zhang H; Ma X; Li L; Wang C; Ma X; Zhang D; Yu H; Zhao L; Ren H; Wang Y; Zhang G; Li C; Du X; Hu X; Li T; Wang Q
Curr Neuropharmacol; 2023; 21(2):424-436. PubMed ID: 36411567
[TBL] [Abstract][Full Text] [Related]
14. Early non-response as a predictor of later non-response to antipsychotics in schizophrenia: a randomized trial.
Long Y; Wu Q; Yang Y; Cai J; Xiao J; Liu Z; Xu Y; Chen Y; Huang M; Zhang R; Xu X; Hu J; Liu Z; Liu F; Zheng Y; Meng H; Wang Z; Tang Y; Song X; Chen Y; Wang X; Liu T; Wu X; Fang M; Wan C; Zhao J; Wu R
BMC Med; 2023 Jul; 21(1):263. PubMed ID: 37468932
[TBL] [Abstract][Full Text] [Related]
15. The advantage of using 3-week data to predict response to aripiprazole at week 6 in first-episode psychosis.
Park JI; Cho DH; Hahn SW; Jeong B; Kim JH; Kim SW; Koo MS; Lee SH; Lee SJ; Lee YH; Park JI; Rho SH; Chung YC
Int Clin Psychopharmacol; 2014 Mar; 29(2):77-85. PubMed ID: 23970176
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone.
Gómez-Revuelta M; Pelayo-Terán JM; Juncal-Ruiz M; Ortiz-García de la Foz V; Vázquez-Bourgon J; González-Pinto A; Crespo-Facorro B
Int J Neuropsychopharmacol; 2018 Dec; 21(12):1090-1101. PubMed ID: 30215723
[TBL] [Abstract][Full Text] [Related]
17. Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach.
Castro-Fornieles J; Parellada M; Soutullo CA; Baeza I; Gonzalez-Pinto A; Graell M; Paya B; Moreno D; de la Serna E; Arango C
J Child Adolesc Psychopharmacol; 2008 Aug; 18(4):327-36. PubMed ID: 18759642
[TBL] [Abstract][Full Text] [Related]
18. Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-naïve patients with a first-episode of non-affective psychosis.
Vázquez-Bourgon J; Pérez-Iglesias R; Ortiz-García de la Foz V; Suárez Pinilla P; Díaz Martínez Á; Crespo-Facorro B
Psychopharmacology (Berl); 2018 Jan; 235(1):245-255. PubMed ID: 29075885
[TBL] [Abstract][Full Text] [Related]
19. Lack of Early Improvement with Antipsychotics is a Marker for Subsequent Nonresponse in Behavioral and Psychological Symptoms of Dementia: Analysis of CATIE-AD Data.
Yoshida K; Roberts R; Suzuki T; Lebowitz B; Reeves S; Howard R; Abe T; Mimura M; Uchida H
Am J Geriatr Psychiatry; 2017 Jul; 25(7):708-716. PubMed ID: 28215900
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
Kane JM; Carson WH; Saha AR; McQuade RD; Ingenito GG; Zimbroff DL; Ali MW
J Clin Psychiatry; 2002 Sep; 63(9):763-71. PubMed ID: 12363115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
